Testing effectiveness (Phase 2)Study completedNCT02423200
What this trial is testing
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Who this might be right for
Alzheimer's Disease
EIP Pharma Inc 16